Rajan Priya V, Wing Deborah A
Maternal-Fetal Medicine, Carolinas Medical Center, University of California, Irvine, California, USA.
Clin Obstet Gynecol. 2010 Mar;53(1):165-81. doi: 10.1097/GRF.0b013e3181ce0965.
Postpartum hemorrhage (PPH) remains a significant contributor to maternal morbidity and mortality throughout the world. The majority of research on this topic has focused on efforts to prevent PPH. Sound data exist that active management of the third stage of labor can reduce the occurrence of PPH. Although there remains debate regarding the optimal protocol for active management, it appears at this time that oxytocin is the preferable uterotonic to use. Misoprostol may be a reasonable option where parenteral administration of an uterotonic is not feasible. There is little evidence to guide treatment decisions should PPH occur.
产后出血(PPH)仍是全球孕产妇发病和死亡的一个重要原因。关于这一主题的大多数研究都集中在预防产后出血的努力上。有可靠数据表明,积极处理第三产程可减少产后出血的发生。尽管对于积极处理的最佳方案仍存在争议,但目前看来,缩宫素是更适宜使用的宫缩剂。在无法进行宫缩剂胃肠外给药的情况下,米索前列醇可能是一个合理的选择。对于产后出血发生时的治疗决策,几乎没有证据可供指导。